By Christian Moess Laursen

PureTech Health said Tuesday it has received up to $11.4 million from the U.S. defense department to advance its therapeutic candidate LYT-300 for treatment of anxiety disorders, postpartum depression and FXTAS, a neurodegenerative disorder.

The biotherapeutics company said the funds will support a Phase II trial of LYT-300--an oral prodrug of allopregnanolone--in collaboration with the University of California, Davis.

FXTAS, or fragile x-associated tremor ataxia syndrome, is a devastating neurological condition closely related to the so-called fragile X syndrome, the company said.

Write to Christian Moess Laursen at christian.moess@wsj.com

(END) Dow Jones Newswires

August 01, 2023 07:35 ET (11:35 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Puretech Health (LSE:PRTC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos Puretech Health.
Puretech Health (LSE:PRTC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos Puretech Health.